Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott glucose meter

This article was originally published in The Gray Sheet

Executive Summary

Firm has received new reports of instances wherein its FreeStyle and FreeStyle Flash blood glucose meters in the U.S. "become inoperable or may revert to a reset condition," potentially leading to a change in the units of measurement and, consequently, misguiding therapy decisions. The July 20 announcement follows a related Class I recall in October 2005. Abbott has issued a letter to healthcare professionals and all customers potentially affected. Meanwhile, it reminds users to check each time they test to make sure the meter's display is correct. J&J/LifeScan has had similar issues with its OneTouch Ultra blood glucose meter (1"The Gray Sheet" Jan. 2, 2006, p. 5)...

You may also be interested in...



FDA Warning Letter Cites J&J Unit For Not Heeding “User Error” Complaints

Johnson & Johnson/LifeScan received a warning letter for neglecting to adequately follow up on frequent reports of user errors associated with its blood glucose meters

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel